has been cited by the following article(s):
[1]
|
Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma
Scientific Reports,
2023
DOI:10.1038/s41598-023-38983-0
|
|
|
[2]
|
Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients
Cancer Chemotherapy and Pharmacology,
2021
DOI:10.1007/s00280-021-04307-0
|
|
|
[3]
|
CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations—Implication for Drug Safety, Dosing, and Individualized Therapy
Frontiers in Genetics,
2021
DOI:10.3389/fgene.2021.692234
|
|
|
[4]
|
The importance of both
CYP2C19
and
CYP2B6
germline variations in cyclophosphamide pharmacokinetics and clinical outcomes
British Journal of Clinical Pharmacology,
2019
DOI:10.1111/bcp.14031
|
|
|
[5]
|
The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes
British Journal of Clinical Pharmacology,
2019
DOI:10.1111/bcp.14031
|
|
|
[6]
|
Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype
Pharmacology Research & Perspectives,
2018
DOI:10.1002/prp2.419
|
|
|
[7]
|
Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6
, CYP2B6
, and CYP3A4
genotype
Pharmacology Research & Perspectives,
2018
DOI:10.1002/prp2.419
|
|
|